Narinder Singh
Technik-/Wissenschafts-/F&E-Leiter bei ARCELLX, INC.
Aktive Positionen von Narinder Singh
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ARCELLX, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.10.2021 | - |
Karriereverlauf von Narinder Singh
Ehemalige bekannte Positionen von Narinder Singh
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
FORTE BIOSCIENCES, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.08.2021 | 01.10.2021 |
AIMMUNE THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 06.07.2020 | 01.07.2021 |
GENOCEA BIOSCIENCES, INC. | Corporate Officer/Principal | 01.03.2018 | 01.07.2020 |
MOMENTA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.07.2015 | 01.03.2018 |
Ausbildung von Narinder Singh
Indian Institute of Technology New Delhi | Graduate Degree |
University of Houston | Graduate Degree |
UCLA Anderson School of Management | Masters Business Admin |
Statistik
International
Vereinigte Staaten | 8 |
Indien | 2 |
Operativ
Chief Tech/Sci/R&D Officer | 3 |
Corporate Officer/Principal | 2 |
Graduate Degree | 2 |
Sektoral
Health Technology | 6 |
Consumer Services | 4 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
GENOCEA BIOSCIENCES, INC. | Health Technology |
ARCELLX, INC. | Health Technology |
FORTE BIOSCIENCES, INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
Momenta Pharmaceuticals, Inc.
Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA. | Health Technology |
Aimmune Therapeutics, Inc.
Aimmune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The firm product include Palforzia, which is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA. | Health Technology |
- Börse
- Insiders
- Narinder Singh
- Erfahrung